Newly-identified protein may contribute to colon cancer development
the ONA take:
A newly-identified pathway may contribute to the development of colon cancer, according to a study published in PLoS Genetics.
Researchers led by Anil Rustgi, MD, of the Perelman School of Medicine at the University of Pennsylvania conducted a follow-up to a 2013 study that identified the LIN28B protein as a contributor of cancerous growth in intestinal cells through suppression of Let-7 molecules.
In the new study, the researchers created transgenic mice that produced no Let-7 miRNAs in order to better understand their function in preventing cancer.
They found that adenomas adenomatous polyps, as well as adenocarcinomas that resembled human colon tumors, had formed in the intestines of all these mice without Let-7 by mid-adulthood.
Upon analyses of the tumors, they were able to identify a protein called Hmga2 as a major factor in their development. They were able to conclude that within the intestinal lining of the mice without Let-7, Hmga2 gene expression was unusually high.
In order to check the relevance of these findings, the researchers also examined several hundred human colorectal cancer samples and found lower-than-normal Let-7 miRNA as well as higher-than-normal HMGA2 (the human version of the mouse Hmga2 protein) expression.
A newly-identified pathway may contribute to the development of colon cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|